From: Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Class | Target | Compound | Clinical phase | Sponsor | Indication | ClinicalTrials.gov identifier | Status/ Results | Reference |
---|---|---|---|---|---|---|---|---|
Small molecules | CSF1R (and cKIT, Flt3) | Pexidartinib (PLX3397, PLX108-01) | 1 | Plexxikon | Solid tumors and extension for MEC, dt-GCT, GIST, ATC, metastatic solid tumors | NCT01004861 | Ongoing ORR: 12/23 (52%) CBR: 19/23 (83%) | [22] |
3 | Plexxikon/Daiichi Sankyo | dt-GCT or GCT-TS | NCT02371369 | Ongoing | - | |||
Monoclonal antibodies | CSF1R | Emactuzumab (RG7155) | 1 | Roche | Solid tumors and dt-GCT | NCT01494688 | ORR: 24/28 (86%) CBR: 27/28 (96% | [12] |
CSF1R | Cabiralizumab (FPA008) | 1/2 | FivePrime | dt-GCT | NCT02471716 | Ongoing | - | |
CSF1 | MCS110 | 2 | Novartis | dt-GCT or GCT-TS | NCT01643850 | Ongoing ORR: 4/4 (100%) | [21] |